Priovant Therapeutics, Inc.

Quick facts

Phase 3 pipeline

• Brepocitinib PO QD · Immunology
  Brepocitinib is a dual JAK1/TYK2 inhibitor that suppresses inflammatory signaling pathways to reduce immune-mediated tissue damage.
• Placebo PO QD
  Placebo has no active pharmacological mechanism and produces therapeutic effects solely through the placebo effect.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Priovant Therapeutics, Inc. portfolio CI brief
• Priovant Therapeutics, Inc. pipeline updates RSS